Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02041091 · ClinicalTrials.gov registry record · Phase 3
A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 226
- Enrollment target
NCT02041091: Clinical Trial Phase 3 study, sponsored by Eli Lilly and Company.
NCT02041091 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 226 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02041091, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 226 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the amount of tabalumab in the blood after it is given by two different injection methods - A traditional syringe or a spring loaded syringe for 12 weeks. Participants may continue to receive study drug for up to 52 weeks.
Primary Outcome
Maximum serum concentration of tabalumab, after the loading dose, assessed over the 14-day dosing interval, stratified by device.PK samples taken during the first dosing interval, days 4, 7, 9, 11, 14, were analyzed using noncompartmental analysis (NCA) methods to calculate the geometric mean.
Interventions
- DRUG Tabalumab Auto-Injector
- DRUG Tabalumab Prefilled Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
Why NCT02041091 stopped before completion
NCT02041091 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which Tabalumab Auto-Injector is the first listed.
NCT02041091 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02041091 about?
NCT02041091 is a clinical study titled "A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus". The purpose of this study is to evaluate the amount of tabalumab in the blood after it is given by two different injection methods - A traditional syringe or a spring loaded syringe for 12 weeks. Participants may continue to receive study drug for up to 52 weeks.
What is the current status of trial NCT02041091?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 226 participants. The study started on 2014-01. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02041091?
The interventions under investigation include: Tabalumab Auto-Injector (DRUG), Tabalumab Prefilled Syringe (DRUG).
Who is sponsoring clinical trial NCT02041091?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02041091's enrollment target sits among peer trials
226 1310th of 2000 higher than 690 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia